InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.43
(
0.48%
)
Bitcoin
62,287.43
(
-1.38%
)
Post# of 640607
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Long_shortguy

Send PM Follow Ignore
Followers 2
Posts 220
Boards Moderated 0
Alias Born 10/03/2019

Long_shortguy

Re: None

Tuesday, 07/28/2020 9:15:43 AM

Tuesday, July 28, 2020 9:15:43 AM

Post# of 640607
$MMEDF:Phase-1 Dosing complete:

https://finance.yahoo.com/news/mindmed-completes-dosing-18-mc-113000940.html

NEW YORK, July 28, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has concluded dosing in a Phase 1 Single Ascending Dose (SAD) study of 18-MC. The dosing of 18-MC was well tolerated in humans and will help advance planning for a Phase 2a clinical trial in opioid addiction. Further, the study has not incurred any delays due to the COVID-19 pandemic and the Multiple Ascending Dose (MAD) study is on track according to the original development timeline.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up